Teva builds its Mylan stake in effort toward becoming generics colossus

Teva ($TEVA) is upping its pressure on takeover target Mylan ($MYL) as the world's largest generics maker continues its march toward turning itself into a generics colossus. This week, Teva increased its stake in Mylan, which has resisted Teva's offers. It now has control of more than 3% of Mylan's shares, giving it enough leverage to submit agenda items at a shareholder meeting next quarter, seen as pivotal in its takeover attempt. Mylan has said it doesn't think antitrust regulators would approve a merger of Teva and Mylan, but Teva claims it has explored that concern and is confident it could. More from FiercePharma

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.